CivicaScript LLC, a nonprofit company focused on bringing low-cost generic medicines to US patients, announced on Tuesday that it will distribute the biosimilar ustekinumab-aauz, used for treatment of chronic inflammatory conditions in certain patients with plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

The product will be available from 1 January 2026. Ustekinumab-aauz is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23, which play an important role in inflammatory and immune responses. The company says that its expansion into biosimilars builds on the steady growth of its specialty generic product portfolio, with four products launched in 2025.

CivicaScript will be the exclusive distributor of unbranded ustekinumab-aauz, produced by Fresenius Kabi. Ustekinumab-aauz is interchangeable to the reference product Stelara (ustekinumab) injection for subcutaneous or intravenous use.

CivicaScript will sell ustekinumab-aauz in prefilled syringes in two different strengths. The Wholesale Acquisition Price (WAC) for a 12-week supply of 90 mg will be USD985 and the WAC for a 12-week supply of 45 mg will be USD575. The biosimilar will be available at this price to CivicaScript's members and partners, including health plans and pharmacy benefit managers.